reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
| Property | Value | Notes |
|---|---|---|
| Common separation technique | Reversed-phase HPLC | Separates mainly by hydrophobicity; gradient elution is typical. |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; also detects many organic impurities. |
| Identity confirmation method | LC-MS or MALDI-MS | Provides molecular mass; not a stand-alone quantitative purity measure. |
| Aggregate assessment method | Size-exclusion chromatography | Detects dimers, oligomers, and larger species. |
| Content assessment method | Amino acid analysis | Estimates peptide mass fraction after hydrolysis and separation. |
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
Peptide purity can change during storage, handling, and reconstitution, and lyophilized peptides are generally more stable than solutions because water promotes hydrolysis and aggregation. Residual moisture, oxygen, and trace metals can accelerate degradation even in solid form. Temperature fluctuations during shipping may cause condensation and local moisture uptake. Quality control therefore includes appearance, water content, and analytical testing before and after storage challenges. Peptides containing cysteine, methionine, or tryptophan are especially susceptible to oxidation, while asparagine and glutamine residues can deamidate under neutral or alkaline conditions.
Analytical quality control compares a stored sample against a baseline profile. Reverse-phase chromatography remains common, but stability studies may also use mass spectrometry to detect oxidation, deamidation, or truncation products. Accelerated aging at elevated temperature can reveal degradation pathways, although extrapolation to room temperature is uncertain. Forced degradation studies expose peptides to heat, light, acid, base, and oxidants to identify likely breakdown products. Documentation should record lot number, storage history, and the exact method used for each measurement.
Handling practices reduce the risk of contamination and degradation. Hygroscopic peptides should be equilibrated to room temperature before opening to prevent condensation on the powder. Weighing and reconstitution in a controlled environment limit exposure to moisture and airborne particles. Aliquotting reconstituted solutions avoids repeated freeze-thaw cycles that can cause aggregation or precipitation. When a purity specification is not met, investigation may consider synthesis byproducts, purification losses, storage conditions, and analytical variability rather than a single cause.
Etifoxine, sold under the trade name Stresam among others, is a nonbenzodiazepine anxiolytic agent, primarily indicated for short-term management of adjustment disorder, specifically instances of situational depression accompanied by anxiety, such as stress-induced anxiety. Administration is by mouth. Side effects associated with etifoxine use include slight drowsiness, headache, skin eruptions, and allergic reactions. In rare cases, etifoxine has been linked to severe skin and liver toxicity, as well as menstrual bleeding between periods. Unlike benzodiazepines, etifoxine does not cause sedation or lack of coordination. Etifoxine acts as a ligand for translocator proteins. Etifoxine was developed in the 1960s and was introduced for medical use in France in 1979. Its marketed in 53 countries worldwide, although it remains unavailable in the United States. Throughout the 2010s and early 2020s, the safety profile of etifoxine was scrutinized within France and the European Union, prompted by reports of toxicity. The investigation revealed that instances of toxicity were infrequent, and etifoxine was allowed to remain on the market.
When injected secretly, it does not have any effect, whereas standard pain drugs have an effect, even if they are administered without the subject's awareness. The supposed mechanism is an enhancement of the neural pathways of expectation as a result of dopamine and endogenous opioids being suddenly released throughout numerous structures of the brain and spinal cord. The ventral tegmental area is the structure believed to mediate proglumide's analgesic and euphoric effects, however dozens of areas with a wide range of physical and psychological functions are implicated in the mediation of the placebo effect (this accounts for proglumide's ability to produce physically measurable effects on vital signs such as heart rate, blood pressure, respiration rate, and tidal volume which cannot be accounted for by its clinically insignificant δ-opioid affinity.
== Children == Pediatric MASLD was first reported in 1983. It is the most common chronic liver disease among children and adolescents since at least 2007, affecting 10 to 20% of them in the US in 2016. MASLD is associated with metabolic syndrome, which is a cluster of risk factors that contribute to the development of cardiovascular disease and type 2 diabetes mellitus. Studies have demonstrated that abdominal obesity and insulin resistance, in particular, are significant contributors to the development of MASFLD. Coexisting liver diseases, such as hepatitis C and cardiovascular diseases such as atherosclerosis, are also associated with an increased risk of MASFLD. Some children were diagnosed as early as two years old, with a mean age of diagnosis between 11 and 13 years old. The mean age is usually above 10 years, as children can also report non-specific symptoms and are thus difficult to diagnose for MASLD. Boys are more likely to be diagnosed with MASLD than girls. Overweight, or even weight gain, in childhood and adolescence, is associated with an increased risk of MASLD later in life, with adult MASLD predicted in a 31-year follow-up study by risk factors during childhood including BMI, plasma insulin levels, male sex, genetic background (PNPLA3 and TM6SF2 variants) and low birth weight, an emerging risk factor for adulthood MASLD. In a study, simple steatosis was present in up to 45% in children with a clinical suspicion of MASLD.
Sources: en.wikipedia.org
Total synthesis, a specialized area within organic chemistry, focuses on constructing complex organic compounds, especially those found in nature, using laboratory methods. It often involves synthesizing natural products from basic, commercially available starting materials. Total synthesis targets can also be organometallic or inorganic. While total synthesis aims for complete construction from simple starting materials, modifying or partially synthesizing these compounds is known as semisynthesis. Natural product synthesis serves as a critical tool across various scientific fields. In organic chemistry, it tests new synthetic methods, validating and advancing innovative approaches. In medicinal chemistry, natural product synthesis is essential for creating bioactive compounds, driving progress in drug discovery and therapeutic development. Similarly, in chemical biology, it provides research tools for studying biological systems and processes. Additionally, synthesis aids natural product research by helping confirm and elucidate the structures of newly isolated compounds. The field of natural product synthesis has progressed remarkably since the early 19th century, with improvements in synthetic techniques, analytical methods, and an evolving understanding of chemical reactivity. Today, modern synthetic approaches often combine traditional organic methods, biocatalysis, and chemoenzymatic strategies to achieve efficient and complex syntheses, broadening the scope and applicability of synthetic processes.
=== Other elements === Not all elements which are found in the human body in trace quantities play a role in life. Some of these elements are thought to be simple common contaminants without function (examples: caesium, titanium), while many others are thought to be active toxins, depending on amount (cadmium, mercury, lead, radioactives). In humans, arsenic is toxic, and its levels in foods and dietary supplements are closely monitored to reduce or eliminate its intake. Some elements (silicon, boron, nickel, vanadium) are probably needed by mammals also, but in far smaller doses. Bromine is used by some (though not all) bacteria, fungi, diatoms, and seaweeds, and opportunistically in eosinophils in humans. One study has indicated bromine to be necessary to collagen IV synthesis in humans. Fluorine is used by a number of plants to manufacture toxins but in humans its only known function is as a local topical hardening agent in tooth enamel.
=== Interactions === Venlafaxine should be taken with caution when using St John's wort. Venlafaxine may lower the seizure threshold, and coadministration with other drugs that lower the seizure threshold such as bupropion and tramadol should be done with caution and at low doses.
== History == Isavuconazole and isavuconazonium were discovered in Japan by researchers at Roche's research center in Kamakura. Basilea Pharmaceutica, which had been spun out of Roche to develop antimicrobial assets, developed isavuconazonium through Phase II clinical trials. In February 2010, Basilea partnered with Astellas Pharma to complete Phase III trials, obtain regulatory approvals, and market the drug. In 2013 and 2014, the partners won orphan drug designation in the US for isavuconazonium for treating invasive aspergillosis, mucormycosis, and invasive candidiasis. In 2014, Basilea and Astellas amended the agreement to give Astellas sole marketing authority in North America, and Basilea the rights to market in the rest of the world. The US Food and Drug Administration (FDA) granted approval in March 2015, and the European Medicines Agency (EMA) approved it in October 2015. In 2017, Basilea licensed rights to Pfizer to market isavuconazole in Europe and other regions.
Sources: en.wikipedia.org
Between 2012 and 2017, the birth rate was 14.3 per thousand and the mortality rate was 10.4 per thousand: even though the Rate of natural increase is positive it does not compensate for the clearly negative net migration rate (-0.7%). In 2017 19% of Le Havre's population was under 15 years old and 39% were under 30 years old, which was above the average for metropolitan France. 24% of men and 26% of women were over 60 years old. The most populous quarters are the city centre, Sanvic, Caucriauville, Anatole France/Danton and Côte Ouest/Ormeaux. In 2009 the foreign population was estimated at 8,525 persons or 4.8% of the population. 12,148 immigrants lived in Havre, or 6.8% of the urban population. Most had North African (5060) or African (3114) origins. With the economic changes that have affected the city, the Professions and Socio-professional categories (PCS) have changed dramatically since the 1980s: between 1982 and 1999, the number of workers has declined by about a third (−10,593), their share of the active labour force was 16% in 1982 and 12.5% in 1999. The population of workers is concentrated in the southern suburbs close to the port and the industrial zone. At the same time the numbers of executives and intellectual professions increased by 24.5%, which is explained in part by the creation and development of the University of Le Havre. In 2017 the city had a lower proportion of managers and intellectual occupations than the national average (14.4% against 18.1%). The proportion of workers (22.5%) was higher than the national average (19.9%).
Cycling extract is a cell-free system derived from Xenopus eggs that autonomously undergoes repeated S phase and M phase cycles. It is prepared by artificially inducing intracellular responses that mimic fertilization, typically through calcium ionophore treatment or electrical stimulation of unfertilized eggs, followed by mechanical crushing of the eggs. This extract has been instrumental in elucidating fundamental mechanisms of cell cycle regulation. For example, it revealed that entry into M phase depends on the translation of cyclin B, which in turn activates maturation promoting factor (MPF). Cycling extracts are primarily used to study the regulation of cell cycle progression.
== Analytical methods == Given the large diversity of PFAS structures that exist, analytical methods for PFAS analysis generally take one of two different approaches: targeted analysis or non-targeted analysis. Targeted methods narrow focus on known PFAS of concern (e.g. PFOA, PFOS) and generally use solid-phase extraction with liquid chromatography–mass spectrometry (LC-MS) detection. For example, EPA Method 537.1 is approved for use in drinking water and can quantify 18 PFAS compounds, while EPA Method 1633A is approved for use for wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue for 40 PFAS chemicals. Regulatory limits for PFOA and PFOS set by the US EPA (4 parts-per-trillion) are limited by the capability of targeted methods to detect low-level concentrations. Non-targeted analyses often sacrifice the identification and quantification of specific PFAS compounds to better understand the amount of PFAS present as a class. For example, total organic fluorine (TOF) analysis quantifies the amount of fluoride produced when a sample is oxidized at high enough temperatures to break the carbon-fluorine bond using combustion ion chromatography. Variants of this analysis include adsorbable organic fluorine (AOF) and extractable organic fluorine (EOF), which use similar solid-phase extraction approaches as the targeted analysis, but use combustion ion chromatography (CIC) as a detector.
Sources: en.wikipedia.org
RP-HPLC purity is the relative area of the main peptide peak compared with the total integrated peak area. It reflects ultraviolet-absorbing species under one set of separation conditions. It does not identify every impurity or measure biological activity.
Chromatographic conditions such as column chemistry, gradient slope, mobile-phase additives, and detection wavelength affect peak resolution. Sample preparation and integration rules also influence area percent values. Without a shared reference standard and validated method, direct comparisons remain uncertain.
Purity describes the proportion of the main peak among detected components. Peptide content measures the amount of the target peptide in a sample after accounting for counterions, water, and residual salts. A sample can have high chromatographic purity but lower net peptide content.
Lyophilized powders are typically kept desiccated at -20 °C or below. Reconstituted solutions require a defined buffer, pH, and storage condition based on available stability data.